US5602242A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hybrid RNA virus
Assignee: Corteva Agriscience LLC
•
Filing: 1995-05-22
•
Granted: 1997-02-11
•
Expires: 2015-05-22
Abstract
Abstract A recombinant RNA virus is provided allowing encapsidation of genetically engineered viral sequences in heterologous, preferably rod-shaped coat, protein capsids. Since icosahedral viruses are limited in the amount of RNA they can carry, and rod-shaped viruses are expansible, this invention allows the size of recombinant virus RNA components to be increased (or decreased). Methods of making and using such recombinant viruses are also provided, specifically with respect to the transfection of plants to bring about genotypic and phenotypic changes.
Inventors
- 👤 Paul G. Ahlquist
- 👤 Roy C. French
- 👤 Robert F. Sacher
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 13:55
CPC Classifications
C; C12; C12N; C12N7/00; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/82; C12N15/8201; C12N15/8202; C12N15/8203; C12N2770/00; C12N2770/00011; C12N2770/00022; C12N2770/00023; C12N2770/14011
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
146 words
A hybrid RNA molecule capable of infection of and replication in a host cell, said hybrid RNA molecule comprising a first RNA sequence derived from a first virus and a second RNA sequence from a second virus have a morphologically-different type of coat protein, said second RNA sequence comprising an origin of assembly and encoding a coat protein heterologous to said first virus, wherein the coat protein gene of said first virus is deleted from or inactivated in said first RNA sequence and said second RNA sequence is substituted therefor to produce a hybrid RNA molecule capable of expressing the coat protein gene of said second virus, and wherein said hybrid molecule is constructed in vitro from said first virus RNA sequence and said second RNA sequence, or wherein said hybrid molecule is descended from a nucleic acid molecule constructed in vitro using recombinant DNA technology.
Claim 2
Dependent Claim
146 words
A hybrid RNA molecule capable of infection of and replication in a host cell, said hybrid RNA molecule comprising a first RNA sequence derived from a first virus and a second RNA sequence from a second virus have a morphologically-different type of coat protein, said second RNA sequence comprising an origin of assembly and encoding a coat protein heterologous to said first virus, wherein the coat protein gene of said first virus is deleted from or inactivated in said first RNA sequence and said second RNA sequence is substituted therefor to produce a hybrid RNA molecule capable of expressing the coat protein gene of said second virus, and wherein said hybrid molecule is constructed in vitro from said first virus RNA sequence and said second RNA sequence, or wherein said hybrid molecule is descended from a nucleic acid molecule constructed in vitro using recombinant DNA technology.
Claim 3
Dependent Claim
12 words
A molecule of claim 1 which is capable of encapsidation in vivo.
Claim 4
Dependent Claim
19 words
A molecule of claim 1 further comprising a sequence heterologous to said first virus which encodes a functional protein.
Claim 5
Dependent Claim
13 words
A molecule of claim 1 wherein said first virus is an icosahedral virus.
Claim 6
Dependent Claim
13 words
A molecule of claim 1 wherein said first virus is a rod-shaped virus.
Claim 7
Dependent Claim
13 words
A molecule of claim 1 having a length greater than about 3.2 kb.
Claim 8
Dependent Claim
18 words
A molecule of claim 1 wherein the origin of assembly and coat protein gene are derived from TMV.
Claim 9
Dependent Claim
16 words
A molecule of claim 1 wherein said RNA sequence from said first virus is BMV RNA3.
Claim 10
Dependent Claim
13 words
A molecule of claim 1 wherein said first virus is a plant virus.
Claim 11
Dependent Claim
140 words
A hybrid RNA molecule capable of infection of and replication in a host cell, said hybrid RNA molecule comprising an RNA segment derived from a first non-rod-shaped virus and an RNA sequence from a second rod-shaped virus, said second virus RNA sequence encoding an origin of assembly and coat protein heterologous to said first virus, wherein said second virus RNA sequence is placed in a region of the RNA segment of said first virus to produce a hybrid RNA molecule, wherein said region is able to tolerate such sequence without disrupting RNA replication of or infection by said hybrid RNA molecule, and wherein said hybrid molecule is constructed in vitro from said first virus RNA segment and said second RNA sequences, or wherein said hybrid molecule is descended from a nucleic acid molecule constructed in vitro using recombinant DNA technology.
Claim 12
Dependent Claim
140 words
A hybrid RNA molecule capable of infection of and replication in a host cell, said hybrid RNA molecule comprising an RNA segment derived from a first non-rod-shaped virus and an RNA sequence from a second rod-shaped virus, said second virus RNA sequence encoding an origin of assembly and coat protein heterologous to said first virus, wherein said second virus RNA sequence is placed in a region of the RNA segment of said first virus to produce a hybrid RNA molecule, wherein said region is able to tolerate such sequence without disrupting RNA replication of or infection by said hybrid RNA molecule, and wherein said hybrid molecule is constructed in vitro from said first virus RNA segment and said second RNA sequences, or wherein said hybrid molecule is descended from a nucleic acid molecule constructed in vitro using recombinant DNA technology.
Claim 13
Dependent Claim
120 words
A hybrid RNA molecule capable of infection of and replication in a host cell, said hybrid RNA molecule comprising a BMV RNA3 sequence and an RNA sequence comprising an origin of assembly and encoding a coat protein derived from TMV, wherein the BMV coat protein gene is deleted from or inactivated in said BMV RNA3 sequence and said TMV RNA sequence is substituted therefor to produce a hybrid RNA molecule capable of expressing the coat protein encoded by said TMV RNA sequence, and wherein said hybrid molecule is constructed in vitro from said BMV RNA3 sequence and said TMV RNA sequence, or wherein said hybrid molecule is descended from a nucleic acid molecule constructed in vitro using recombinant DNA technology.
Claim 14
Dependent Claim
120 words
A hybrid RNA molecule capable of infection of and replication in a host cell, said hybrid RNA molecule comprising a BMV RNA3 sequence and an RNA sequence comprising an origin of assembly and encoding a coat protein derived from TMV, wherein the BMV coat protein gene is deleted from or inactivated in said BMV RNA3 sequence and said TMV RNA sequence is substituted therefor to produce a hybrid RNA molecule capable of expressing the coat protein encoded by said TMV RNA sequence, and wherein said hybrid molecule is constructed in vitro from said BMV RNA3 sequence and said TMV RNA sequence, or wherein said hybrid molecule is descended from a nucleic acid molecule constructed in vitro using recombinant DNA technology.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-11 | 2000-08-12 | 2001-02-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-11 | 2004-08-12 | 2005-02-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-11 | 2008-08-12 | 2009-02-11 | $7700.00 | Window Closed / Lapsed |